APGE Reports $1.3B Cash Position, Advances Zumilokibart Pipeline, $403M Equity Raise, Phase 3 AD Trials Expected H2 2026
Apogee Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $79.30
-3.8% in 7d after detection
Post-detection moves
1h
—
1d
-2.0%
3d
-0.8%
7d
-3.8%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS